Coverage
-
February 11, 2015
The plaintiff suing Allergan Inc.'s board of directors for failing to properly consider Valeant Pharmaceuticals International Inc.'s takeover bid on Wednesday decided to voluntarily dismiss the derivative class action, citing Valeant's decision to withdraw its own offer.
1 other articles on this case.
View all »